Captopril
Protease inhibitor: ACE. Targets viral cell entry via inhibition of ACE2. Gordon et al. bioRxiv, Mar 23 2020, https://doi.org/10.1101/2020.03.22.002386.
- Datasheet: view or download
- Applications:Approved drug (U.S.) that could be repurposed
Biochemicals & reagents
62571-86-2
1) Cushman et al. (1999), Design of angiotensin converting enzyme inhibitors; Nat.Med. 5 1110 2) Orning et al. (1991), Inhibition of leukotriene A4 hydrolase/aminopeptidase by captopril; J.Biol.Chem. 266 16507
217.28
-20°C (des.)
Captopril is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 = 0.022 μM (1) which also inhibits the bifunctional Zn2+-containing leukotriene A4 hydrolase/aminopeptidase (LTA4 hydrolase) reversibly and competitively (Ki = 6.0 μM for leukotriene B4 formation and Ki = 60 nM for L-lysine-p-nitroanilide) (2). This comound displays vasodilatory and antihypertensive effects in vivo and is a clinically useful antihypertensive agent.